Latest: FDA Approves New Biosimilar for Oncology Treatment

ANGLE partners with Myriad Genetics to explore blood-based cancer testing

by PharmaTimes

14 September, 2025

0 Mins

ANGLE has announced a collaboration with Myriad Genetics to assess whether circulating tumour cell (CTC) DNA harvested from blood samples using ANGLE’s Parsortix system can be used alongside Myriad’s existing tissue-based diagnostic assays.

Tags:

Author

PharmaTimes

Friends of Cancer Research and MMS partner to improve interpretation of cancer trial survival data

Employers Uncertain About Affording Employer-Sponsored Health Plans Within the Next 3 Years

📢

300x250 Banner

ANGLE partners with Myriad Genetics to explore blood-based cancer testing

Tags:

PharmaTimes

Friends of Cancer Research and MMS partner to improve interpretation of cancer trial survival data

Employers Uncertain About Affording Employer-Sponsored Health Plans Within the Next 3 Years

Recent Content

COPD Biologics: Early Treatment Insights

Antihypertensive Medication Guidelines

Juvenile Arthritis Care Transition